Ductal Carcinoma In Situ

FangMeng Fu; Richard C Gilmore; Lisa K Jacobs

doi:10.1016/j.suc.2018.03.007

Ductal Carcinoma In Situ

Surg Clin North Am. 2018 Aug;98(4):725-745. doi: 10.1016/j.suc.2018.03.007. Epub 2018 May 28.

Authors

FangMeng Fu¹, Richard C Gilmore², Lisa K Jacobs³

Affiliations

¹ Fujian Medical University Union Hospital, 29 Xinquan Rd, DongJieKou SangQuan, Gulou Qu, Fuzhou Shi, Fujian Sheng 350001, China.
² Johns Hopkins Hospital, The Johns Hopkins University School of Medicine, 1800 Orleans Street, Baltimore, MD 21287, USA.
³ Johns Hopkins Hospital, The Johns Hopkins University School of Medicine, 1800 Orleans Street, Baltimore, MD 21287, USA. Electronic address: Ljacob14@jhmi.edu.

PMID: 30005770
DOI: 10.1016/j.suc.2018.03.007

Abstract

Ductal carcinoma in situ has been stable in incidence for a decade and has an excellent prognosis. Breast conservation therapy is safe and effective for most patients. Adjuvant whole breast radiation therapy is recommended to reduce the risk of local recurrence. Accelerated partial breast irradiation is a promising alternative to decrease toxicity and improve cosmetic results. Adjuvant hormonal therapy can reduce local recurrence, but should be used cautiously. Future directions in management include developing predictive tools for guidance for use of adjuvant therapy and selecting low-risk patients with ductal carcinoma in situ in whom surgery may be safely omitted.

Keywords: Breast cancer; Ductal carcinoma in situ; Hormonal therapy; Incidence; Mortality; Radiation therapy.

Publication types

Review

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use
Breast Neoplasms / diagnosis*
Breast Neoplasms / epidemiology
Breast Neoplasms / therapy*
Carcinoma, Intraductal, Noninfiltrating / diagnosis*
Carcinoma, Intraductal, Noninfiltrating / epidemiology
Carcinoma, Intraductal, Noninfiltrating / therapy*
Combined Modality Therapy
Female
Humans
Mastectomy, Segmental
Patient Selection

Substances

Antineoplastic Agents, Hormonal